Bristol, Ambrx team up to develop antibody-based cancer drugs

05/6/2013 | Genetic Engineering & Biotechnology News

Bristol-Myers Squibb and Ambrx agreed to co-develop antibody drug conjugates for cancer with the latter's protein medicinal technology. Ambrx will receive $15 million upfront and as much as $97 million in research funding and milestone fees for each product, plus sales royalties. Bristol will get the global rights to develop and market the drugs arising from the partnership.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC